Nykredit A S Makes New $177.13 Million Investment in Gilead Sciences, Inc. $GILD

Key Points

• Nykredit A/S acquired 1.4 million Gilead Sciences shares worth approximately $177.1 million, representing a 0.11% stake. Institutional investors and hedge funds collectively own 83.67% of the company.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $158.04; Zacks recently upgraded the stock to “Strong Buy.”
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year and above estimates, while declaring a quarterly dividend of $0.82 per share. Insiders sold $14.5 million of stock over the past three months, including sales conducted under pre-arranged trading plans.

Nykredit A S purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,402,025 shares of the biopharmaceutical company's stock, valued at approximately $177,132,000. Nykredit A S owned 0.11% of Gilead Sciences as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the fourth quarter worth about $25,000. Persistent Asset Partners Ltd bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $25,000. Kimelman & Baird LLC bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC raised its position in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 85 shares during the period. Finally, Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $26,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 15,000 shares of Gilead Sciences stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the completion of the transaction, the chief executive officer directly owned 577,133 shares of the company's stock, valued at $85,785,049.12. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider owned 118,234 shares in the company, valued at approximately $16,273,727.76. This represents a 19.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,000 shares of company stock worth $14,495,820 in the last three months. Insiders own 0.30% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on GILD shares. Zacks Research upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday. Weiss Ratings lowered shares of Gilead Sciences from a "buy (b-)" rating to a "hold (c-)" rating in a report on Tuesday, August 11th. Maxim Group raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price target on the stock in a research report on Wednesday, May 20th. Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $120.00 to $123.00 and gave the company a "sector perform" rating in a report on Wednesday, August 5th. Finally, Morgan Stanley lowered their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating for the company in a research report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $158.04.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Zacks upgraded Gilead to “Strong Buy.” The upgrade reflects improving expectations for the company’s earnings outlook and could encourage additional buying interest. Gilead Upgraded to Strong Buy
• Positive Sentiment: Zacks raised its 2027 EPS forecasts across every quarter and for the full year. Estimates increased to $2.09 for Q1, $2.24 for Q2, $2.43 for Q3, $2.60 for Q4 and $9.36 for full-year 2027, signaling modestly stronger anticipated profitability. Zacks Gilead Upgrade and Forecasts
• Positive Sentiment: FDA approval of Bixlenvo expands Gilead’s HIV portfolio. The single-tablet treatment is aimed at underserved patients and could provide a new source of growth, though commercial adoption will determine its financial impact. Bixlenvo HIV Growth Opportunity
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The transaction reduced his holdings by 2.53%, but it was executed under a pre-arranged Rule 10b5-1 plan, making it a weaker bearish signal than an unexpected discretionary sale. SEC Insider Trading Filing

Gilead Sciences Price Performance

Shares of GILD opened at $149.61 on Thursday. The stock has a 50 day simple moving average of $135.66 and a 200 day simple moving average of $136.45. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a market capitalization of $185.51 billion, a PE ratio of -56.03 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm had revenue of $7.80 billion during the quarter, compared to analysts' expectations of $7.40 billion. During the same quarter in the prior year, the company earned $2.01 EPS. The company's revenue was up 10.6% on a year-over-year basis. Sell-side analysts predict that Gilead Sciences, Inc. will post -0.47 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences's dividend payout ratio is presently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source